Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Carol Cronenberger, Sarah Hackley, Hideto Kameda, Sebastião Cezar Radominski, Muhammad I. Rehman, Rieke Alten, Michael L. Tee, Alan Kivitz, Stanley Cohen, Oliver von Richter, Min Zhang
Publikováno v:
Biodrugs
Objective Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks
Autor:
Igor Bondarenko, Maciej Bryl, Kazuo Kasahara, Vladimir Ivanovich Vladimirov, Manuela Zereu, Kostas N. Syrigos, Niels Reinmuth, Angel H. Bair, Fiona Hilton, K. F. Liau
Publikováno v:
Biodrugs
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-lin
Autor:
Jessica B Jordan, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Luis-Emilio Garcia-Perez, Ren Yu, Syed Wasi Hassan, Dara Stein
Publikováno v:
Drugs in R&D
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Introduction Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is to add a
Autor:
Ahmed A. Othman, Ben Klünder, Peter Noertersheuser, Mohamed-Eslam F. Mohamed, Anna Friedel, Rajendar K. Mittapalli
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses cha
Autor:
Alfredo Berrocal Kasay, Thomas Linde, Piotr Wiland, Elia Chalouhi El-Khouri, Sang Joon Lee, Pavel Shesternya, Francisco Fidenci Cons Molina, Janusz Jaworski, Ihor Hospodarskyy, Paweł Hrycaj, Jose Chavez-Corrales, Mauricio Abello-Banfi, Marek Brzosko, Sergii Shevchuk, Seung Cheol Shim, Dae Hyun Yoo, Armando Calvo, D. Andersone, Sławomir Jeka, Chang-Hee Suh, Sung Young Lee, Francisco G. Medina-Rodriguez, Pedro Miranda, Marek Krogulec, Won Park, Mariusz Piotrowski
Publikováno v:
Biodrugs
Objective The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid art
Publikováno v:
Clinical Pharmacokinetics
Background Intravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which ma